Ⅱ/Ⅲ期乳腺癌采用CEF方案联合赫赛汀靶向治疗的临床研究  

Clinical study on CEF chemotherapy regimen combined with Herceptin targeted therapy in treatment of stage Ⅱ/Ⅲ breast cancer

作　　者：黄永惠[1] HUANG Yong-Hui(Department of Oncology,Longchang County People＇s Hospital,Neijiang,Sichuan 642150,China)

机构地区：[1]内江市隆昌县人民医院肿瘤科,四川内江642150

出　　处：《中国妇幼保健》2018年第16期3824-3826,共3页Maternal and Child Health Care of China

摘　　要：目的探讨赫赛汀靶向治疗Ⅱ/Ⅲ期乳腺癌的疗效,为临床提供参考。方法选择2014年11月-2015年11月隆昌县人民医院肿瘤科的收治的124例Ⅱ/Ⅲ期乳腺癌的患者为研究对象,按照随机数字表的分配原则分成对照组与观察组,每组各62例。对照组给予CEF方案化疗,观察组应用CEF方案联合赫赛汀治疗。两组均治疗3周,两组患者在化疗后进行手术治疗。治疗后比较两组的临床疗效,不良反应发生率。同时用KPS评价患者的生活质量,比较两组患者在治疗后的生活质量评分。结果治疗后,观察组治疗总的有效率为87.1%,对照组治疗总的有效率54.8%,两组比较差异有统计学的意义(P<0.05)。两组治疗后的KPS评分优于治疗前,观察组治疗后的KPS评分优于对照组,差异有统计学的意义(P<0.05)。观察组与对照组的不良反应发生率分别为27.4%和32.2%,两组比较差异没有统计学的意义(P>0.05)。结论赫赛汀靶向治疗Ⅱ/Ⅲ期乳腺癌的临床疗效,患者的预后生活质量高。Objective To explore the clinical efficacy of Herceptin targeted therapy in treatment of stage Ⅱ/Ⅲ breast cancer,provide reference for clinical treatment. Methods From November 2014 to November 2015,124 patients with stage Ⅱ/Ⅲ breast cancer treated in Department of Oncology,Longchang County People＇s Hospital were selected and divided into control group and observation group according to random number table,62 patients in each group. The patients in control group were treated by CEF chemotherapy regimen. The patients in observation group were treated by CEF chemotherapy regimen combined with Herceptin targeted therapy. The patients in the two groups were treated for three weeks. Operation was performed after chemotherapy in the two groups. After treatment,the clinical effects and the incidence rates of adverse reactions were compared between the two groups. The quality of life of the patients was evaluated by KPS. The scores of life quality after treatment in the two groups were compared. Results After treatment,the total effective rates in observation group and control group were 87. 1% and 54. 8%,respectively,there was statistically significant difference between the two groups（ P〈0. 05）. KPS scores after treatment in the two groups were statistically significantly better than those before treatment（ P〈0. 05）. KPS score after treatment in observation group was statistically significantly better than that in control group（ P〈0. 05）. The incidence rates of adverse reactions in observation group and control group were 27. 4% and 32. 2%,respectively,there was no statistically significant difference between the two groups（ P〉0. 05）. Conclusion The clinical effect of Herceptin targeted therapy in treatment of stage Ⅱ/Ⅲ breast cancer is significant,the prognosis is good,and the quality of life is high.

关 键 词：CEF化疗方案 Ⅱ/Ⅲ期乳腺癌 赫赛汀 

分 类 号：R453[医药卫生—治疗学]